中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

10 records (took 0.013 seconds)

    Gradient coated stent and method of fabrication
    2.
    发明申请
    Gradient coated stent and method of fabrication 有权
    梯度涂层支架及其制造方法

    公开(公告)号：US20050075714A1

    公开(公告)日：2005-04-07

    申请号：US10921735

    申请日：2004-08-18

    Applicant: Peiwen Cheng ,  Patrice Tremble ,  Wenda Carlyle ,  Diane Judd ,  Kishore Udipi

    Inventor： Peiwen Cheng ,  Patrice Tremble ,  Wenda Carlyle ,  Diane Judd ,  Kishore Udipi

    IPC: A61F2/00 ,  A61F2/02 ,  A61F2/90 ,  A61F2/06

    CPC classification number: A61F2/86 ,  A61F2/0077 ,  A61F2/91 ,  A61F2/915 ,  A61F2/958 ,  A61F2002/072 ,  A61F2002/91541 ,  A61F2210/0004 ,  A61F2230/0054 ,  A61F2250/0067 ,  A61L31/10 ,  A61L31/16 ,  A61L2300/41 ,  A61L2300/416 ,  A61L2300/45 ,  A61L2300/606

    Abstract: The gradient coated stent 150 of the present invention provides a coated stent having a continuous coating 130 disposed on the stent elements. The continuous coating 130 includes a first coating component and a second coating component. The concentration of the first coating component varies continuously over at least part of the thickness of the continuous coating 130. The concentration of the second coating component can also vary over at least part of the thickness of the continuous coating 130. In one embodiment, the concentration of the first coating component decreases in the direction from the stent element towards the outer edge of the continuous coating 130 and the concentration of the second coating component increases in the direction from the stent element towards the outer edge of the continuous coating 130.

    Abstract translation: 本发明的梯度涂层支架150提供了涂层支架，其具有设置在支架元件上的连续涂层130。 连续涂层130包括第一涂层组分和第二涂层组分。 第一涂层组分的浓度在连续涂层130的厚度的至少一部分上连续变化。第二涂层组分的浓度也可以在连续涂层130的至少一部分厚度上变化。在一个实施方案中， 第一涂层组分的浓度在从支架元件朝向连续涂层130的外边缘的方向上减小，并且第二涂层组分的浓度在从支架元件朝向连续涂层130的外边缘的方向上增加。

    Medical devices comprising a protein-tyrosine kinase inhibitor to inhibit restonosis
    3.
    发明申请
    Medical devices comprising a protein-tyrosine kinase inhibitor to inhibit restonosis 审中-公开
    包含抑制再狭窄的蛋白质 - 酪氨酸激酶抑制剂的医学装置

    公开(公告)号：US20050214343A1

    公开(公告)日：2005-09-29

    申请号：US10490248

    申请日：2003-07-17

    Applicant: Patrice Tremble ,  Wenda Carlyle

    Inventor： Patrice Tremble ,  Wenda Carlyle

    IPC: A61F2/00 ,  A61F2/86 ,  A61K31/506

    CPC classification number: A61F2/86 ,  A61F2250/0067 ,  A61K31/506

    Abstract: Implantable medical devices having an anti-restenotic coatings are disclosed. Specifically, implantable medical devices having coatings of proteintyrosine kinase inhibitors are disclosed. The anti-restenotic protein-tyrosine kinase inhibitor is 4+4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2pyrimidinyl]amino]-phenyl]benzamide methanesulfonate and pharmaceutically acceptable derivatives thereof (imatinib mesylate). The anti-restenotic medial devices include stents, catheters, micro-particles, probes and vascular grafts. The medical devices can be coated using any method known in the art including compounding the protein-tyrosine kinase inhibitor with a biocompatible polymer prior to applying the coating. Moreover, medical devices composed entirely of biocompatible polymer-protein-tyrosine kinase inhibitor blends are disclosed. Additionally, medical devices having a coating comprising at least one proteintyrosine kinase inhibitor in combination with at least one additional therapeutic agent are also disclosed. Furthermore, related methods of using and making the antirestenotic implantable devices are also disclosed.

    Abstract translation: 公开了具有抗再狭窄涂层的植入式医疗装置。 具体地，公开了具有蛋白酪氨酸激酶抑制剂的涂层的可植入医疗装置。 抗再狭窄蛋白酪氨酸激酶抑制剂是4 + 4-甲基-1-哌嗪基）甲基] -N- [4-甲基-3 - [[4-（3-吡啶基）-2-嘧啶基]氨基] - 苯基]苯甲酰胺 甲磺酸盐及其药学上可接受的衍生物（甲磺酸伊马替尼）。 抗再狭窄的内侧装置包括支架，导管，微粒，探针和血管移植物。 医疗装置可以使用本领域已知的任何方法进行包衣，包括在施加涂层之前将蛋白质 - 酪氨酸激酶抑制剂与生物相容性聚合物混合。 此外，公开了完全由生物相容性聚合物 - 蛋​​白 - 酪氨酸激酶抑制剂共混物组成的医疗装置。 此外，还公开了具有包含至少一种蛋白酪氨酸激酶抑制剂与至少一种另外的治疗剂组合的包衣的医疗装置。 此外，还公开了使用和制造抗再狭窄植入式装置的相关方法。

    Use of Fatty Acids to Inhibit the Growth of Aneurysms
    4.
    发明申请
    Use of Fatty Acids to Inhibit the Growth of Aneurysms 审中-公开
    使用脂肪酸抑制动脉瘤的生长

    公开(公告)号：US20070231361A1

    公开(公告)日：2007-10-04

    申请号：US11277637

    申请日：2006-03-28

    Applicant: David Brin ,  Jack Chu ,  Prema Ganesan ,  Dianne Judd ,  Michel Letort ,  Patrice Tremble ,  Eugene Tedeschi

    Inventor： David Brin ,  Jack Chu ,  Prema Ganesan ,  Dianne Judd ,  Michel Letort ,  Patrice Tremble ,  Eugene Tedeschi

    IPC: A61K31/202

    CPC classification number: A61K31/202

    Abstract: Methods of treating an aneurysm in a patient in need thereof are provided. The methods comprise delivering to a treatment site an effective amount of a fatty acid inhibitor of a matrix metalloproteinase (MMP) such that the fatty acid inhibitor of the MMP causes the regression of a pre-existing aneurysm. Additionally, an implantable medical device is provided for implanting in a vessel wall of a patient comprising a structural support and a fatty acid inhibitor of an MMP.

    Abstract translation: 提供了在有需要的患者中治疗动脉瘤的方法。 所述方法包括向治疗部位递送有效量的基质金属蛋白酶（MMP）的脂肪酸抑制剂，使得MMP的脂肪酸抑制剂导致预先存在的动脉瘤的消退。 另外，可植入医疗装置用于植入患者的血管壁，包括结构支持物和MMP的脂肪酸抑制剂。

    Method and agent for treating vulnerable plaque
    7.
    发明申请
    Method and agent for treating vulnerable plaque 审中-公开
    治疗易损斑块的方法和药剂

    公开(公告)号：US20050260157A1

    公开(公告)日：2005-11-24

    申请号：US10531851

    申请日：2003-09-16

    Applicant: Patrice Tremble ,  Wenda Carlyle

    Inventor： Patrice Tremble ,  Wenda Carlyle

    IPC: A61K48/00 ,  C12N15/86

    CPC classification number: A61K48/0083 ,  A61K48/005 ,  A61K48/0075

    Abstract: A method and gene therapy agent for treating a vulnerable plaque associated with a blood vessel of a patient is disclosed. The method includes providing at least one gene therapy agent encoding at least one protein. The gene therapy agent is administered to a target cell population. The protein is expressed within the patient from a portion of the target cell population. The vulnerable plaque is modified as a result of the protein expression. The gene therapy agent includes at least one polynucleic acid encoding at least one protein. Administration of the gene therapy agent to a target cell population results in expression of the protein capable of modifying the vulnerable plaque.

    Abstract translation: 公开了一种用于治疗与患者血管相关的易损斑块的方法和基因治疗剂。 该方法包括提供编码至少一种蛋白质的至少一种基因治疗剂。 将基因治疗剂施用于靶细胞群体。 蛋白质在靶细胞群体的一部分内在患者体内表达。 由于蛋白质表达，脆性斑块被修饰。 基因治疗剂包括编码至少一种蛋白质的至少一种多核酸。 将基因治疗剂施用于靶细胞群体导致能够修饰易损斑块的蛋白质的表达。

    Gradient coated stent and method of fabrication
    8.
    发明授权
    Gradient coated stent and method of fabrication 有权
    梯度涂层支架及其制造方法

    公开(公告)号：US08801692B2

    公开(公告)日：2014-08-12

    申请号：US10921735

    申请日：2004-08-18

    Applicant: Peiwen Cheng ,  Patrice Tremble ,  Wenda Carlyle ,  Diane Judd ,  Kishore Udipi

    Inventor： Peiwen Cheng ,  Patrice Tremble ,  Wenda Carlyle ,  Diane Judd ,  Kishore Udipi

    IPC: A61M31/00 ,  A61F2/06 ,  A61L33/00

    CPC classification number: A61F2/86 ,  A61F2/0077 ,  A61F2/91 ,  A61F2/915 ,  A61F2/958 ,  A61F2002/072 ,  A61F2002/91541 ,  A61F2210/0004 ,  A61F2230/0054 ,  A61F2250/0067 ,  A61L31/10 ,  A61L31/16 ,  A61L2300/41 ,  A61L2300/416 ,  A61L2300/45 ,  A61L2300/606

    Abstract: The gradient coated stent 150 of the present invention provides a coated stent having a continuous coating 130 disposed on the stent elements. The continuous coating 130 includes a first coating component and a second coating component. The concentration of the first coating component varies continuously over at least part of the thickness of the continuous coating 130. The concentration of the second coating component can also vary over at least part of the thickness of the continuous coating 130. In one embodiment, the concentration of the first coating component decreases in the direction from the stent element towards the outer edge of the continuous coating 130 and the concentration of the second coating component increases in the direction from the stent element towards the outer edge of the continuous coating 130.

    Abstract translation: 本发明的梯度涂层支架150提供了涂层支架，其具有设置在支架元件上的连续涂层130。 连续涂层130包括第一涂层组分和第二涂层组分。 第一涂层组分的浓度在连续涂层130的厚度的至少一部分上连续变化。第二涂层组分的浓度也可以在连续涂层130的至少一部分厚度上变化。在一个实施方案中， 第一涂层组分的浓度在从支架元件朝向连续涂层130的外边缘的方向上减小，并且第二涂层组分的浓度在从支架元件朝向连续涂层130的外边缘的方向上增加。

    Methods for Compounding and Delivering a Therapeutic Agent to the Adventitia of a Vessel
    10.
    发明申请
    Methods for Compounding and Delivering a Therapeutic Agent to the Adventitia of a Vessel 审中-公开
    将治疗剂复合并递送至血管外膜的方法

    公开(公告)号：US20090204104A1

    公开(公告)日：2009-08-13

    申请号：US11568779

    申请日：2005-05-04

    Applicant: Patrice Tremble ,  Dianne Judd ,  Kishore Udipi ,  Peiwen Cheng ,  Rangarajan Sundar ,  Kaushik A. Patel ,  Eugene Tedeschi

    Inventor： Patrice Tremble ,  Dianne Judd ,  Kishore Udipi ,  Peiwen Cheng ,  Rangarajan Sundar ,  Kaushik A. Patel ,  Eugene Tedeschi

    IPC: A61M25/10 ,  A61M25/06 ,  A61K9/14 ,  A61P9/02

    CPC classification number: A61M25/0084 ,  A61K9/16

    Abstract: The invention provides a method of delivering a therapeutic agent to the adventitia of a vessel using a catheter-based microsyringe. A therapeutic agent is formed into microparticles, which are dispersed throughout an appropriate liquid carrier to form a therapeutic mixture. A catheter is provided that includes a microsyringe operably attached to an actuator. The microsyringe includes a hollow needle in fluid communication with a therapeutic agent delivery conduit. The catheter is introduced into a target area of a vessel. The actuator is operated to thrust the needle into a wall of the vessel. The therapeutic mixture is supplied to the therapeutic agent delivery conduit and delivered through the conduit to the needle and thereby into the adventitia of the vessel. The actuator is again operated to withdraw the needle from the wall of the vessel and to enclose it within the actuator. The catheter is then removed from the vessel.

    Abstract translation: 本发明提供了使用基于导管的微量注射器将治疗剂递送至血管外膜的方法。 将治疗剂形成为微粒，其分散在适当的液体载体中以形成治疗性混合物。 提供了一种导管，其包括可操作地附接到致动器的微量注射器。 微量注射器包括与治疗剂输送管道流体连通的中空针头。 将导管引入血管的靶区域。 致动器被操作以将针推入容器的壁中。 将治疗性混合物供应到治疗剂递送导管并通过导管输送到针，从而被输送到血管的外膜。 致动器再次被操作以将针从容器的壁中抽出并将其封闭在致动器内。 然后从血管中取出导管。

Patent Agency Ranking